US Stock Market Move | Vertex Pharmaceuticals Incorporated (VRTX.US) surged after hours as the late-stage trial of the kidney drug povetacicept met its expected target.

In after-hours trading on Monday, the stock price of Vertex Pharmaceuticals Incorporated (VRTX.US) briefly rose by 11%, but by the time of writing, the increase had narrowed to 5%. The biotechnology company had previously announced that its drug for treating kidney disease had met its target in late-stage trials, giving a boost to its strategy of surpassing cystic fibrosis treatment. As of Monday's closing, the company's stock price had risen by 1.7% year-to-date. The company stated that patients treated with povetacicept had a 52% reduction in urinary protein levels after 36 weeks compared to baseline. Vertex Pharmaceuticals also stated that the drug had shown overall safety and good tolerability in a study involving over 605 patients. Based in Boston, Vertex Pharmaceuticals Incorporated has been expanding beyond its core business of cystic fibrosis treatment. Sales of its gene-editing therapy for sickle cell anemia and beta-thalassemia have been slow, and the company has been working to secure insurance coverage for its newly launched pain reliever, Journavx. Vertex Pharmaceuticals Incorporated stated that it plans to complete its application to the U.S. Food and Drug Administration (FDA) for povetacicept by the end of March and seek an accelerated approval process. The company mentioned that they plan to use a priority review voucher to shorten the review period from 10 months to 6 months. Vertex Pharmaceuticals Incorporated acquired povetacicept for about $4.9 billion in its acquisition of Alpine Immune Sciences Inc. in 2024. This transaction is the largest acquisition in Vertex's history. Povetacicept can block two inflammatory proteins called cytokines, which sometimes stimulate the body to attack its own tissues. The company has been testing the therapy's effectiveness against a kidney disease called IgA nephropathy, which affects approximately 1.5 million people worldwide. Many patients with this disease progress to end-stage kidney failure, which can be fatal.